"$25,000 per patient for 120 patients, single injection as out patient is more than than ample over one year and perhaps $40,000 total per patient with the second year follow-up."???
No. Not how clinical trial spending works. Again, WHY are they out trying to drub up $60 MILLION in cold hard cash, via pure dilution? Why? And why did they open and file, on the record, a $100 MILLION shelf to have available to tap-out as needed? Because $100 MILLION is a well known industry "average" to conduct a typical pharma-bio phase II. That $100 million number is published all over the place in financial and journal articles discussing the costs of clinical trials. $100 million is actually on the low side for a decent phase II.
So why is mgt out seeking an initial $60 Ma MILLION? Cause they know they're gonna need it, that's why. It costs big money to draft SEC filings and prospectus documents and file and hire law firms to put all that together, as well as, hire qty-3 underwriters. Those people don't show up and work for free. They've probably spend $500K already just in setting the table to "try" and get that funding in place.
It's nice just to invent imaginary numbers- but those numbers have never been seen or heard of in any phase II in modern times I'm familiar with? Management wouldn't be out hunting for large money for no reason. $3 to $5 mil is noise level money- they'd just use Lincoln in that case and be done with it. Again, they're already consuming about $2 million a month and that's running no trials right now.
